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Abstract
Several Hsp90 modulators have been identified including the N-terminal ligand geldanamycin 
(GDA), the C-terminal ligand novobiocin (NB), and the co-chaperone disruptor celastrol. Other 
Hsp90 modulators elicit a mechanism of action that remains unknown. For example, the natural 
product gedunin and the synthetic anti-spermatogenic agent H2-gamendazole, recently identified 
Hsp90 modulators, manifest biological activity through undefined mechanisms. Herein, we report 
a series of biochemical techniques used to classify such modulators into identifiable categories. 
Such studies provided evidence that gedunin and H2-gamendazole both modulate Hsp90 via a 
mechanism similar to celastrol, and unlike NB or GDA.
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The 90kDa heat shock proteins (Hsp90) are essential for both refolding denatured proteins 
as well as the conformational maturation of several nascent polypeptides into their 
biologically active structure. Hsp90-dependent client proteins are associated with signaling 
cascades in normal cells. However, regulation of cell signaling and proliferation is necessary 
in tumor cells due to their highly stressed environments, and Hsp90 is critical for 
maintaining their survival. Hsp90 inhibition has been shown to block several oncogenic 
signaling nodes responsible for regulating the six hallmarks of cancer simultaneously. 
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Consequently, Hsp90 has emerged as a viable target for the development of cancer 
chemotherapeutic.1–3
Other disease states are also attenuated through modulation of Hsp90. Rheumatoid arthritis 
is an inflammation inducing autoimmune disease characterized by the aberrant penetration 
of immune system cells into joint synovial tissue along with the pseudo-oncogenic growth 
and proliferation of synovial fibroblasts and their invasion into surrounding cartilage. 
Inhibition of the Nf-kB pathway has been proposed as a treatment option for RA, and 
indeed, several proteins in this pathway are Hsp90-dependent, including RIP, IKK, and 
JNK, among others.4
Alzheimer’s is a disease characterized by the accumulation of misfolded-proteins that 
demonstrates positive mediation by Hsp90 modulators. 5 The accumulation of β-amyloid 
(Aβ) oligomers in the brain has been shown to result in neurodegeneration. These Aβ 
aggregates initiate a cascade that leads to the hyper-phosphorylation and misfolding of tau 
protein, inflammatory reactions and cytotoxicity. 6 By stimulating the rematuration of 
misfolded proteins, Hsp90 induction has emerged as a potential strategy for the treatment of 
Alzheimer’s disease, thereby promoting the search for non-toxic, small molecule Hsp90 
modulators that induce the heat shock response, resulting in the overexpression of Hsp27, 
Hsp40, Hsp70, Hsp90 and associated proteins.7
Currently, significant efforts are underway to develop both known and novel Hsp90 
inhibitors.8–12 Such a process would likely benefit from the development of a set of 
experiments by which Hsp90 modulators can be mechanistically differentiated.
Modulators of Hsp90 have been found to interact primarily at two locations, the C- and N-
termini of the protein. The Hsp90 N-terminus contains a nucleotide-binding domain that is 
responsible for the hydrolysis of ATP, which provides the requisite source of energy for the 
protein folding machinery. Binding and hydrolysis of ATP is mediated by at least two 
distinct Hsp90 conformations. Upon binding ATP, the N-terminal domains dimerize and 
adopt the clamped conformation. This induces protein folding, after which, ATP is 
hydrolyzed to ADP, forcing Hsp90 to adopt its open conformation and eventually, to 
facilitate client protein release.13
The N-terminal ATP binding pocket has been the focus of intense drug discovery efforts. 
The natural product inhibitors GDA (Figure 1) and radicicol, as well as their derivatives, 
bind to this site and prevent formation of the clamped conformation, and instead induce the 
open conformational state.14,15 These compounds cause the accumulation of “intermediate” 
Hsp90 complexes incapable of proper folding by preventing the binding and hydrolysis of 
ATP (15). This serves to destabilize Hsp90-client complexes, and ultimately leads to client 
protein degradation via the ubiquitin-proteasome pathway.8,9
A second site of modulation is located near the N-terminus at the interface between Hsp90 
and the kinase co-chaperone Cdc37. Experiments using small interfering RNA (siRNA) 
have shown that Cdc37 knockdown, in effect a complete disruption of Hsp90/Cdc37 
interactions, leads to selective degradation of kinase client proteins, and strongly sensitizes 
Hsp90 to inhibition by GDA and other N-terminal inhibitors.16–18 The natural product 
Matts et al. Page 2













celastrol was identified as the first small molecule disruptor of this interaction.19 Two 
mechanisms have been proposed to describe how celastrol manifests this activity. Through 
molecular modeling experiments, it was suggested by Zhang et al. that celastrol occupies the 
Cdc37 binding site on Hsp90, and blocks Cdc37 from occupancy.20 However, Sreeramulu et 
al. observed the formation of celastrol/Cdc37 Michael adducts in solution, thereby 
suggesting celastrol covalently modifies Cdc37 cysteine residues, and therefore acts via 
irreversible inhibition.21
The C-terminus of Hsp90 is responsible for formation of the stable Hsp90 homodimer 
complex and contains a second nucleotide-binding sit.1,22,23 The C-terminus, in concert with 
the middle domain of Hsp90, is also capable of mediating Hsp90’s interactions with client 
proteins, promoting or preventing the binding of co-chaperones and immunophillins, and 
modulating ATPase activity. 24–26 It has been demonstrated that NB (Figure 1), a previously 
identified DNA gyrase inhibitor, binds the C-terminal nucleotide pocket and displaces both 
ATP and other ligands from the N-terminus. However, NB is a poor inhibitor, and 
modulates Hsp90 function at ~700 μM. In addition, Neckers and coworkers have shown that 
the N-terminal ATP-binding site must be occupied before the C-terminal site is 
accessible.27,28
An advantage of C-terminal versus N-terminal inhibition is lack of the heat shock 
response. 29 N-terminal inhibition results in displacement of heat shock factor 1 (HSF1), the 
transcription factor responsible for activation of the heat shock response.30 Under normal 
conditions, Hsp90 binds HSF1, but in the presence of cellular stress or N-terminal inhibitors, 
this complex is disassembled and HSF1 translocates to the nucleus as a phosphorylated 
trimer that binds the heat shock binding elements.31 Several modulators of Hsp90 function 
have been identified based on the NB scaffold and have been shown to induce client protein 
degradation without induction of the heat shock response.29,32–34
Some members of the NB-based class of compounds exhibit differing biological profiles. 
For example, KU32 induces a pronounced heat shock response upon incubation with cells at 
concentrations far below that needed to induce client protein degradation (unpublished 
results). The natural product gedunin has demonstrated Hsp90 inhibitory activity but does 
not compete with GDA for binding to the N-terminus.19,35 Similarly, H2-gamendazole 
manifests Hsp90 inhibitory activity via an unknown mechanism of action.36 In an effort to 
delineate the varying modes of Hsp90 modulation, as well as to develop techniques to affirm 
an Hsp90 inhibitor’s mechanism of action, several Hsp90 inhibitors, including GDA, NB 
A4, A4-dimer, KU32, KU174, KU135, celastrol, gedunin, and H2-gamendazole (Figure 2) 
have been systematically evaluated for their effects on Hsp90 and their phenotypic profiles 
in cancer and yeast cells through proteolytic fingerprinting, affinity chromatography, co-
immunoprecipitation, and induction of the heat shock response.
NB and GDA are two well-known Hsp90 inhibitors that have undergone extensive 
biochemical characterization.10,15,27,28,37–40 They serve as both chemical tools and 
standards for which the biological activities to which other Hsp90 modulators are compared. 
Proteolytic fingerprints of Hsp90 in the presence of GDA or NB are quite different. Hsp90 
in the presence of GDA or without ligand provides the same proteolytic fingerprint upon 
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incubation with trypsin, i.e. proteolytic cleavage occurs at Arg 291, Lys 399, and Arg 612 
(corresponding to mammalian Hsp90β numbering). Trypsin treatment of Hsp90 incubated 
with NB provides a fingerprint that results in cleavage at Arg 291 and Lys 399, but not Arg 
612 (mHsp90β). In a complementary manner, affinity chromatography provides additional 
data for GDA and NB.39,41 For example, when rabbit reticulocyte lysate (RRL) is applied to 
a GDA-sepharose column, Hsp90 is retained on the column, and can be eluted with 
increasing concentrations of GDA or NB. Conversely, when RRL is applied to a NB-
sepharose column, Hsp90 is retained on the column and can be eluted with increasing 
concentrations of NB, but not GDA.27,28 This differential activity for N-terminal and C-
terminal inhibitors can be applied to further classify new modulators.
For Hsp90 modulators that do not result in either GDA or NB proteolytic fingerprints or 
similar chromatographic results, other mechanisms, such as disruption of Hsp90-
cochaperone interactions, may be responsible for the observed inhibitory activities. In such 
cases, co-immunoprecipitation experiments can be used to further clarify the mechanism of 
action.
A library of NB Analogues
A library of NB analogues was designed to probe the essential nature of several residues 
found on the natural product and to expeditiously reveal modifications that could enhance 
Hsp90 modulation. All compounds were prepared in 1 M stock solutions in DMSO.
Reagents
The anti-Hsp90 antibodies used to detect proteolytic fragments of Hsp90 were obtained as 
follows. The AC88 monoclonal antibody recognizes the C-terminus of Hsp90 and was 
obtained from Stressgen. The affinity-purified polyclonal rabbit antibodies raised against a 
peptide representing the N-terminus of mouse Hsp86 were obtained from Affinity 
BioReagents, Inc (PA3-013). GDA was a gift from Infinity Pharmaceuticals. Molybdate was 
obtained from Sigma Chemical Co. All drugs were prepared as a 1M stock and stored as 
single use aliquots at −20°C.
Proteolytic Fingerprinting of Hsp90
TnT rabbits reticulocyte lysate was incubated under conditions for protein synthesis at 37 °C 
in the presence of drug or vehicle control for 5 min. The protein folding reaction mixtures 
contained 50% (v/v) rabbit reticulocyte lysate, an ATP regenerating system (10mM creatine 
phosphate and 20 units/mL creatine phosphokinase), and 75 mM KCl. The reaction mixtures 
contained drug/control as indicated. After incubation, the reaction mixtures were chilled on 
ice, followed by digestion with the indicated amount of TPCK-treated trypsin (Worthington) 
at the indicted concentrations. After digestion on ice for 6 min, reactions were stopped by 
immediate boiling in SDS-PAGE sample buffer. Samples were separated by SDS-PAGE 
and subjected to Western blot analysis using antibodies specific to the N-terminus of Hsp90 
(PA3-013 Affinity BioReagents) or the C-terminus of Hsp90 (AC88, Stressgen).
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NB affinity column chromatography
Three grams of epoxy-activated sepharose 6B (Sigma Chemical Co.) was washed and 
swollen in 100 mL of distilled water for 1 hr at room temperature. The resin was washed 
further with coupling buffer (0.3 M sodium carbonate pH 9.5). The gel was mixed with 400 
mg of NB (sodium salt, Sigma Chemical Co.) in 10 mL of coupling buffer and incubated at 
37 °C with gentle rotation for 20 hours. The excess ligand was washed away with coupling 
buffer, and the remaining epoxy-active groups were blocked with 1 M ethanolamine in 
coupling buffer for 12 hours at 30 °C with gentle shaking. The gel was thoroughly washed 
sequentially with coupling buffer, 0.5 M NaCl in coupling buffer, distilled water, 0.5 M 
NaCl in 0.1 M sodium acetate (pH 4.0), and again in distilled water. It was then equilibrated 
in 25 mM HEPES (pH 8.0) containing 1mM EDTA, 10% ethylene glycol, and 200 mM KCl 
and kept at 4 °C protected for light.
Preparation of GDA affinity beads
Briefly, GDA was derivatized and immobilized as follows: 1,6-hexanediamine was added to 
GDA (10 mM in chloroform) at a 10 fold molar excess and allowed to react for 2 hours. 
After aqueous extraction, 17-hexamethylenediamine-17-demethoxyGDA was dried, 
redissolved in DMSO, and reacted with AffiGel 10 resin (Bio-Rad Laboratories). Before 
use, the GDA AffiGel beads were washed in buffer (50 mM Tris-HCl (pH 7.4), 1% P-40, 2 
mM EDTA, 100 mM NaCl, and 1 mM sodium orthovanadate) and blocked with 1% bovine 
serum albumin.
RRL system and ATP regenerating reaction mixtures were incubated for 5 min under 37 °C 
in order to induce Hsp90 expression. After the RRL system was applied to the column and 
equilibrated with the coupling buffer (0.3 M sodium carbonate pH 9.5), it was washed with 
20 volumes of the buffer containing 0.15 M NaCl. After washing the column, binding 
proteins were eluted with a linear gradient of drugs (0~5 mM) in the same buffer. All these 
experiments were carried out in the dark at 4 °C. The eluents were analyzed on SDS/PAGE 
(12.5 % gel) with anti-Hsp90 antibody.
Hsp90 coimmunoprecipitation
SKBr-3 cells were treated with vehicle, celastrol, gedunin and H2-gamendazole. GDA and 
NB were used as control. Cells were lysed in 20 mM Tris HCl (pH 7.4), 25 mM NaCl, 2 
mM DDT, 20 mM Na2MoO4, 0.1 % NP-40, and protein inhibitors. Lysates were incubated 
for 2 hr at 4°C while rotating, and then centrifuged at 14,000×g for 10 min. Protein (500 μg) 
was incubated with anti-Hsp90 antibody for 2 hrs at 4°C. Protein G agarose (40 μl) was 
added to each sample, and samples were then incubated overnight at 4°C. The beads were 
washed with the same lysis buffer. Bound proteins were isolated by boiling in sample buffer, 
and subjected to SDS-PAGE, coimmunoprecipitating proteins were analyzed by western 
blot analysis.
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Regulation of oncoproteins involved in tumor proliferation
MCF-7 cells were maintained in a 1:1 mixture of Dulbecco’s modified Eagle’s medium, 
Ham’s F-12 (Gibco) supplemented with nonessential amino acids, L-glutamine (2 mM), 
streptomycin (500μg/mL), penicillin (100 units/mL), and 10% fetal bovine serum. Cells 
were grown to confluence in a humidified atmosphere (37°C, 5% CO2), seeded in culture 
dishes (1×106/dish), and allowed to attach overnight. Compounds were added at varying 
concentrations and returned to the incubator for 48 h. Cells were harvested and analyzed for 
Hsp90 client protein degradation as described previously.42
β-galactosidase assay
PP30 yeast strain expressing Hsp90a as their sole Hsp9043 was transformed with the 
centromeric URA3 vector, pHSE,44 constitutively expressing β-galactosidase (encoded by 
lacz) as a reporter gene under control of a promoter bearing 3× Heat Shock Element (HSE) 
response elements.44 Transformants were selected by DO medium (dropout 2% glucose 
medium) supplemented with appropriate amino acids without uracil.45 Yeast cells were 
grown overnight to exponential phase with a cell density of 2–3×106 cells per ml in 50ml of 
the same medium at 30°C. Then, appropriate compounds were added to a final concentration 
of 30μM, followed by incubation at 30°C for 2h. Cells were additionally heat shocked at 
39°C for 1h, collected by centrifugation (2000×g; 5 minutes), washed once with ddH2O, and 
frozen at −80°C. The proteins were extracted as previously described,46 except for exclusion 
of EDTA in the extraction buffer. β-Galactosidase activities of HSE were measured as 
previously described.47 Cell lysate (10μl) was mixed with equal volume of 2×buffer Z 
(0.12M Na2HPO4.7H2O, 0.08M NaH2PO4.H2O, 0.02M KCl, 0.002M MgSO4) pH 7.0. 
The mixture was added to 700μl of 2mg/ml ONPG solution in 1×buffer Z prewarmed at 
30°C and incubated at 30°C for 5–30 minutes. The reaction was stopped by adding 500μL of 
1M Sodium Carbonate. The optical density at 420nm (OD ) of each reaction mixture was 
determined. The protein concentration of the lysate was 420 determined by the BioRad 
assay (BioRad). The β-galactosidase activity was calculated using the following formula: 
.
Small molecule effects on the proteolytic fingerprint of Hsp90
We first studied the effect of GDA and NB on the conformation of Hsp90 from RRL in 
order to reproduce previously reported fingerprints. In agreement with previous work (39, 
41), Hsp90 exhibited a different proteolytic fingerprint upon treatment with NB or GDA. 
The proteolytic fingerprint of Hsp90 in the presence of GDA was identical to the fingerprint 
produced upon treatment with vehicle control (Hsp90 is completely degraded by high 
concentrations of trypsin, suggesting that GDA has no effect on the protease sensitivity of 
Hsp90) (Figure 3). This fingerprint corresponds to trypsinolysis at several amino acid 
residues, including Arg 291, Lys 399, and Arg 612 (mHsp90β). Also in agreement with 
literature precedent, the proteolytic fingerprint of Hsp90 upon incubation with increasing 
concentrations of NB (Figure 3), in the presence of relatively high concentrations of trypsin 
(~125 μg/mL), resulted in a prominent band at 40 kDa, and no 78 kDa band was observed 
with antibody to the N-terminal domain. In contrast, the most prominent band occurs at 50 
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kDa upon immunoblotting with a C-terminus antibody. When using relatively low 
concentrations of trypsin, both NB and GDA treated assays failed to show a strong band at 
40 kDa (data not shown). With the proteolytic fingerprints of both NB and GDA re-
established, trypsinolysis of Hsp90 in the presence of other Hsp90 modulators were 
compared.
We applied the fingerprint evaluation protocol to RRL incubated with Hsp90 modulators 
KU32, KU174, KU135, A4, A4-dimer, coumermycin A1, H2-gamendazole, celastrol and 
gedunin, and compared these data to those obtained with NB and GDA (Figure 3). The 
Hsp90 fragments resulting from trypsinolysis after incubation of RRL with NB-derived 
compounds KU32, KU174, KU135, A4, and A4-dimer, as well as coumermycin A1 were 
similar to those observed for NB. The most prominent band occurred following immunoblot 
with the C-terminal antibody. All of the NB analogues demonstrated the property of 
efficiently blocking trypsinolysis at the same amino acid residue as NB, Arg 612 
(mHsp90β). This amino acid residue is proximal to the amino acid sequence between 657 
and 677, which was discovered by Marcu et al. to be critical for C-terminal ligand 
binding.27,28 These data support the conclusion that NB and its derivatives induce similar 
conformational effects on Hsp90, thereby suggesting a similar mode of binding for these 
compounds.
The Hsp90 proteolytic fingerprints observed from RRL incubated with H2-gamendazole, 
celastrol, and gedunin were unique when compared to the fingerprints obtained from RRL 
incubated with GDA or NB (Figure 3). When immunoblotting with the N-terminal antibody, 
a 78 kDa band was observed as the major band, suggesting that celastrol, gedunin, and H2-
gamendazole all bind Hsp90 and efficiently block trypsin cleavage at amino acid residues 
Arg 291 and Lys399, unlike GDA, but do not block cleavage at Arg 612 (mHsp90β), unlike 
NB. When the C-terminal antibody was used, several weak bands appeared, however, no 
major band at 50 kDa was observed, unlike both GDA and NB. This provides further 
evidence to support the conclusion that these compounds are blocking cleavage at Hsp90 
residues Arg 291 and Lys 399 (mHsp90β), and are inducing conformational effects distinct 
from GDA, NB, and NB derivatives. Also, this provides strong evidence that celastrol, 
gedunin, and H2-gamendazole exhibit their effects by direct interactions with Hsp90.
Computational rationalization of Hsp90 conformations and trypsinolysis 
results
To provide a plausible structural basis to explain these experimental data, computational 
analyses were conducted that included sequence-based analyses of cleavage sites and 
subsequent structural analyses of the cleavage sites environment in different Hsp90 crystal 
and solution structures.
Probable cleavage of the HtpG (bacterial Hsp90) sequence by trypsin was first explored in 
silico by using PeptideCutter48 and OPAL (http://www.oppf.ox.ac.uk/opal/OPAL.php) 
approaches and respective web-based servers with the objective of gaining information 
about potential cleavage sites and their location. PeptideCutter1 is a specialized tool that 
allows searching for possible cleavage sites in a protein sequence and predicting the 
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probability of cleavage. The OPAL approach and server provides information about the 
probable cleavage sites ranked according to cleavage rate. A comparative analysis of the 
cleavage sites in the E. coli Hsp90 sequence has revealed a number of possible cleavage 
sites in the Hsp90 sequence. The experimentally observed Arg-291, Lys-399, and Arg-612 
residues, which correspond to HtpG residues Arg-291, Lys-398, and Arg-616 respectively, 
were predicted by PeptideCutter to be amongst the sites that exhibit the highest cleavage 
probability of 100%, 94.9 %, and 82.6% respectively. A similar result was obtained from the 
OPAL server (Table 1), indicating these sites are predictable by different in silico tools.
Emerging structural and biochemical data has suggested that the Hsp90 molecular chaperone 
may exist in a conformational equilibrium between the open apo-form, the ADP-bound 
compact, and the ATP-closed bound protein state, which have been reported in previously 
solved crystal and solution structures. Comparison of Arg-291, Lys-398, and Arg-616 
(HtpG) residues in the three conformations (open solution, semi-closed and closed) provided 
insight into the potential structural form of Hsp90 that binds NB (Figure 4). In the semi-
closed and closed conformation of Hsp90, Arg-616 (HtpG) resides on the surface in an α-
helix, and is fully exposed to the solvent. In the open, solution form, Arg-616 (HtpG) lies at 
the interface between the two monomers and is slightly obscured due to the presence of 
other residues. Hence, the probability of trypsinolysis at the Arg-616 (HtpG) position may 
be greater for the semi-closed and closed conformation as compared to open conformation in 
which it is less solvent exposed.
We have followed with the analysis of solvent accessible surface area (SASA) for the 
cleavage sites in different crystal structures of Hsp90 to evaluate whether Arg616 can be 
accessible by trypsin in these conformational states. Our calculations rationalized the 
experimental data and asserted structural preferences for NB binding, since it is reasonable 
to assume that NB may bias the Hsp90 equilibrium toward a structural form that is not 
readily amenable to trypsinolysis.
When the solvent accessibilities were calculated for the three conformations, it was found 
that in the open conformation, the Arg-616 (HtpG) residue resides in a low solvent 
accessibility (~24 Å2) as compared to the semi-closed (~93 Å2) conformation (Table 2), 
since it exists in a cavity at the interface of the two monomeric species, while in other 
conformations it remains on the surface. Thus, cleavage in the open structure is likely to be 
more difficult, since there is insufficient space for a protein the size of trypsin to bind 
Arg616 (HtpG).
Effects of NB analogues, celastrol, gedunin, and H2-gamendazole on 
affinity chromatography using NB- and GDA-sepharose beads
Determination that NB interacted with the C-terminus of Hsp90 was originally reported 
based on affinity purification experiments.27,28 NB immobilized on sepharose beads 
demonstrated the retention of a C-terminal fragment of Hsp90, but not an N-terminal 
fragment. Also, increasing concentrations of GDA were found insufficient for the elution of 
Hsp90 from a NB-sepharose column. In contrast, however, an increasing concentration of 
NB eluted Hsp90 from GDA-immobilized sepharose beads. Other compounds that manifest 
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similar activity to NB indicate a similar mode of binding and would provide a 
confirmational screen for newly discovered Hsp90 modulators that bind the C-terminus.
To reproduce the previously reported data, RRL was applied to either GDA or NB 
immobilized on sepharose beads and washed with 0.15M NaCl to remove non-specific 
binding proteins. The beads were then subjected to elution conditions with either increasing 
concentrations of GDA or NB (Figure 5, A and B). Results from these experiments 
confirmed those previously reported. With the proper conditions in hand, we evaluated the 
NB derived compounds KU32, KU135, KU174, A4, and the A4 dimer, as well as celastrol, 
gedunin, and H2-gamendazole in identical experiments (Figure 5, A, B, and C).
When using increasing concentrations of the NB-derived compounds to elute the bound 
Hsp90 from either the NB- or GDA-sepharose beads, Hsp90 was eluted from the column. 
Washing the NB- or GDA-sepharose beads with NB derived compounds produced the same 
effect as that observed with the parent compound. These data suggest that the NB-derived 
compounds bind Hsp90 similarly to NB.
When using celastrol, gedunin, or H2-gamendazole in increasing concentrations with GDA-
sepharose, Hsp90 was eluted, but only at very high concentrations. However, Hsp90 was not 
eluted when the NB sepharose beads were washed with these compounds at high 
concentrations. These data suggest that celastrol, gedunin and H2-gamendazole affect Hsp90 
in a distinct manner from that of N- and C-terminal inhibitors.
Celastrol, gedunin and H2-gamendazole disrupt interactions between 
Hsp90 and the cochaperone Cdc37 in SKBr-3 cells
Recently, it was reported that celastrol manifests anti-proliferative activity by disrupting 
formation of the Hsp90/Cdc37 complex, however, the mechanism by which celastrol 
manifests this activity has been disputed. It has been reported that celastrol binds Hsp90 at 
the Cdc37/Hsp90 protein interface. In contrast, it has also been reported that celastrol 
manifests its activity by covalently modifying cysteine residues on Cdc37, and subsequently 
preventing Cdc37 from binding Hsp90. Since the observed effects of gedunin and H2-
gamendazole on Hsp90 in both the proteolytic fingerprint and affinity chromatography 
assays were identical to the effects of celastrol, gedunin and H2-gamendazole may elicit 
their anti-proliferative effects via a similar mechanism.
To determine whether gedunin and H2-gamendazole disassemble the Hsp90/Cdc37 
complex, co-immunoprecipitation experiments were conducted. SKBr-3 breast cancer cells 
were incubated for 24 hours with increasing concentrations of celastrol, gedunin, H2-
gamendazole, NB, and GDA and then lysed with NP-40 lysis buffer (Figure 6).
Lysates were immunoprecipitated with an anti-Hsp90 antibody and Protein G agarose. 
Protein was submitted to SDS-PAGE and analyzed by immunoblot, using the Hsp90 and 
Cdc37 antibodies. The control compounds, GDA and NB, exhibited no effect on the 
concentrations of Cdc37 following Hsp90 immunoprecipitation, in agreement with 
previously reported data,39 as these compounds are unable to disrupt the Cdc37/Hsp90 
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complex. However, celastrol, gedunin and H2-gamendazole, decreased the levels of Cdc37 
in a concentration-dependent manner (Figure 7), supporting the hypothesis that all three 
compounds manifest a similar mechanism of action that results from disruption of the 
Hsp90/Cdc37 complex.
Effects of Hsp90 modulators on client proteins
A hallmark of Hsp90 inhibition is the degradation of Hsp90-dependent client proteins. 
Hsp90 inhibition prevents the maturation of client protein substrates by the generation of 
destabilized complexes between client proteins and the chaperone, resulting in 
ubiquitinylation and subsequent degradation of the client by the proteasome.49 This leads to 
decreased levels of Hsp90 clients in cells and detection of this phenomenon by Western blot 
is commonly employed to confirm Hsp90 inhibition. In addition, a common hallmark of N-
terminal inhibition is the up-regulation of Hsp’s, such as Hsp70, which stems from induction 
of the heat shock response.
MCF-7 cells were incubated with GDA, NB, NB analogues, celastrol, gedunin, or H2-
gamendazole for 24 hours at increasing concentrations (Figure 8). Cells were lysed, 
submitted to SDS-PAGE, and immunoblotted to detect protein levels of the client proteins 
AKT and HER2, and also the cochaperone Hsp70. All compounds demonstrated the 
characteristic degradation of both Her2 and AKT in a dose-dependent manner (Figure 8), 
confirming Hsp90 client protein degradation. This provides strong evidence that Hsp90 is 
the cellular target for these compounds.
In an effort to investigate induction of the heat shock response, Hsp70 levels were also 
evaluated. As an indicator that the NB derivatives and celastrol, gedunin, and H2-
gamendazole do not bind the N-terminal ATP binding pocket, administration of these 
modulators at various concentrations did not result in increased Hsp70 levels.
Evaluation of the heat shock response induced by Hsp90 modulators
Heat shock transcription factor 1 (HSF1) is an Hsp90-dependent client protein that, when 
displaced from Hsp90, results in the heat shock response upon transcriptional activation of 
the heat shock genes by binding to the heat shock binding element. Previous work has 
shown that human Hsp90 is functional in yeast lacking endogenous Hsp90. Therefore, we 
examined the effects of NB and its analogues; KU32, KU135, and KU174, as well as 
coumermycin A1, celastrol, gedunin, and H2-gamendazole on HSF activity. PP30 cells 
expressing hHsp90α (as the only copy of Hsp90) and containing the HSF-lacZ reporter 
(Heat Shock Binding Element, HSE-lacZ) were treated with 100μM of the above 
compounds for 3 hours. In addition, these cells were subsequently stressed upon heat shock 
(39°C) for 1 hour.
Similar to GDA, KU32 induced a heat shock response even in the absence of heat stress 
(Chart 1), whereas NB and KU135 blocked induction of the heat shock response, even upon 
exposure to subsequent heat stress. Finally, KU174, coumermycin A1, celastrol, gedunin, 
and H2-gamendazole exhibited no altered effect on the heat shock response in yeast, 
suggesting these inhibitors do not interfere with Hsp90/HSF1 interactions (Chart 1).
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Hsp90 has emerged as an important molecular target for a variety of therapeutic uses. 
Consequently, a large number of Hsp90 modulators exist, however, it remains unclear as to 
the mechanism by which some of these modulators function. To delineate structure-function 
relationships, we provide a systematic approach toward unraveling the mechanistic features 
manifested by Hsp90 modulators. The combination of proteolytic fingerprinting, affinity 
chromatography, co-immunoprecipitation, and evaluation of the heat shock response have 
been used to characterize and differentiate the modes exhibited by three classes of Hsp90 
modulators. While each technique provides valuable insight into a specific modulatory 
attribute of a given compound, the combined results provide insights into both old and new 
mechanisms of modulation as well as subtle differences between compounds within the 
same inhibitory class.
Among the compounds evaluated by this protocol, several are characterized by inclusion of 
the coumarin heterocyclic scaffold as found in the natural product NB. These compounds 
include the natural product coumermycin A1 and the NB-derived compounds KU32, 
KU135, KU174, A4, and the A4-dimer. A comparison of the proteolytic fingerprint of 
Hsp90 induced upon incubation with these compounds supports a similar mode of binding 
as NB. Unlike the proteolytic fingerprint of Hsp90 when incubated with GDA, these 
compounds blocked trypsin mediated cleavage of Hsp90 at residue Arg 612 (mHsp90β). In 
silico experiments provide additional evidence that these compounds bind Hsp90 in the open 
state, thereby shifting the conformational equilibrium into the open state, wherein residue 
Arg 612 (mHsp90β) is sequestered from the protein surface and unavailable for trypsin 
binding/cleavage.
Affinity chromatography and co-immunoprecipitation provide further, corroborating 
evidence that KU32, KU135, KU174, A4, and the A4-dimer bind similarly to NB. These 
NB-derived compounds displace N-terminal ligands, as demonstrated by their ability to 
elute Hsp90 from a GDA-sepharose column in the same manner as that previously reported 
for NB. In addition, NB and the NB-derived compounds are unable to disrupt interactions 
between Hsp90 and Cdc37, further delineating them from other N-terminal binders.
While effects on Hsp90 conformation, location of binding, and effects on Hsp90 
cochaperone interactions are similar for NB and the NB-derived compounds, their ability to 
induce a heat shock response, are divergent. The NB-derived compound KU32, which was 
similar to NB in all prior evaluations, exhibits a strong induction of heat shock response 
upon incubation with yeast cells at 30°C and 39°C. In contrast, compound KU135, which 
manifests anti-proliferative activity ~1000 fold greater than NB (IC50 of 420 nM in LNCaP 
and 1.05 μM in LN3 prostate cancer cell lines), elicits no heat shock response in yeast, 
similar to NB, and furthermore, prevents induction of the heat shock response at elevated 
temperatures. The remaining NB-derived compound, KU174, which manifests an IC50 of 
2.3 μM in LNCaP and 110 nM in LN3 prostate cancer cells, elicits no heat shock response 
upon incubation with yeast cells, but unlike NB, displays no protective effects against the 
heat shock response upon incubation at higher temperatures.
Strong evidence has been provided that the NB-derived compounds modulate Hsp90 via a 
similar mechanism as NB and proximal to the Hsp90 C-terminal dimer interface. However, 
Matts et al. Page 11













the β-galactosidase assay has provided evidence for the existence of potentially three unique 
modes of C-terminal inhibition, which differ by their effects on induction of the heat shock 
response. Exactly how the C-terminal inhibitors are manifesting this differential heat shock 
response profile is unknown, and further investigation is required.
The proteolytic fingerprint of Hsp90 upon incubation with celastrol, gedunin, and H2-
gamendazole revealed these modulators to induce similar Hsp90 conformational changes 
that are distinct from both N- and C-terminal inhibitors. This provides strong evidence that 
these compounds interact directly with Hsp90, and modulate its activity in a manner distinct 
from GDA and NB. Affinity chromatography revealed these compounds do not compete 
directly with either N- or C-terminal inhibitors of Hsp90.
Celastrol and gedunin were originally identified through the “Connectivity Map” screen, 
which can be used to compare the effects of small molecules on the expression levels of 
mRNA in order to gather information about potential molecular targets. Both of these 
natural products yielded similar results as 17-AAG, and were subsequently validated as 
Hsp90 inhibitors. H2-gamendazole was identified through whole cell studies,36,50 and is 
structurally dissimilar to celastrol and gedunin, but manifests potent anti-spermatogenic 
activity as a result of Hsp90 modulation. The experiments described in this manuscript 
suggest a common mechanism of action for these three compounds, and indeed, co-
immunoprecipitation experiments confirmed that all three compounds effectively disrupt 
Hsp90/Cdc37 interactions.
The natural sources of both celastrol and gedunin, Tripterygium wilfordii Hook F. and 
Azadirachta indica respectively, have also been used in traditional medicine for their anti-
spermatogenic properties. This work has confirmed that all three compounds manifest 
Hsp90 modulation via similar mechanisms, suggesting that gedunin and celastrol may be 
responsible for the observed anti-spermatogenic activity of the whole plant extracts through 
Hsp90 modulation.
This manuscript has detailed the application of proteolytic fingerprinting, affinity 
chromatography, co-immunoprecipitation, and evaluation of the heat shock response as tools 
for exploring and characterizing various mechanisms of Hsp90 modulation (Chart 1).
This systematic protocol can be used as an investigational tool for newly discovered Hsp90 
modulators. While subsequent compound analysis including X-ray crystallography, NMR 
studies, and degradation studies would provide more specific details, the approach outlined 
herin rapidly segregates compounds into various mechanistic classes. As a proof of 
principle, this process has provided evidence that the NB-derived compounds manifest their 
activity through interactions with the C-terminus of Hsp90, similarly to NB. These C-
terminal modulators are promising lead compounds for the development of clinical agents 
with potential applications toward Ahlzeimer’s disease and/or cancer. In addition to 
supporting this hypothesis, this protocol has provided insight into factors governing Hsp 
induction by elucidating three distinct heat shock response profiles that occur through C-
terminal modulation of Hsp90. Finally, three structurally dissimilar Hsp90 modulators, 
celastrol, gedunin, and H2-gamendazole, were verified as disruptors of Cdc37/Hsp90 
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interactions through modulation of Hsp90. These agents are now under investigation for the 
development of male contraceptive and/or anticancer agents.
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Structures of the natural product Hsp90 inhibitors geldanamycin (GDA) and novobiocin 
(NB).
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Structures of Hsp90 modulators under investigation.
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Proteolytic fingerprint of Hsp90 after incubation with modulator. Rabbit reticulocyte lysate 
reaction mixtures containing an ATP regenerating system were incubated for 5 min at 37°C 
in the absence of drug (Wild type with 0, 50 and 125 μg/ml trypsin), in the presence of GDA 
(10 μg/ml), NB (20 mM), NB analogue, KU174, KU32, KU135, A4, A4 dimer, 
coumermycin A1 (10 μM) or H2-gamendazole, Celastrol and gedunin (20 μM). After drug 
treatment, reaction mix were chilled and incubated on ice with trypsin at the indicated 
concentrations. Trypsinolyzed reaction mixtures were boiled in SDS-PAGE buffer and 
analyze by SDS-PAGE and Western blotting with antibodies directed against the N-terminus 
(A) and C-terminal (B) of Hsp90.
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The location of cleavage sites (Arg 291, Lys 398, and Arg616) in different Hsp90 
conformations.
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Affinity Chromatography using NB bound sepharose (A), GDA bound sepharose (B), and 
affinity chromatography results for celastrol (CEL), gedunin (GED), and H2-gamendazole 
(GMZ) at the indicated concentrations. RRL system and ATP regenerating reaction mixture 
were incubated for 5 min at 37°C, applied for the NB-sepharose or GDA-sepharose column, 
after washing with 20 volume buffer, binding Hsp90 is competed by a solution of the 
indicated compound at the indicated concentration. Eluents were detected by anti-Hsp90 
antibody. N5 (NB 5 mM), G5 (GDA 5 μM)
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Celastrol, gedunin and H2-gamendazole decreases Hsp90 interaction with Cdc37. Celastrol, 
gedunin and H2-gamendazole treatement of SKBR-3 cells (5 μM) decreased the amount of 
Cdc37 detected in co-immunoprecipitation with Hsp90, as shown by western blot of the co-
immunoprecipitate and lysate. GDA (10 μM) and NB (1 mM) did not affect the interaction 
of Hsp90 and cdc37, which is shown as a control.
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Dose-dependent activity of Celastrol, gedunin and H2-gamendazole on the Cdc37/Hsp90 
complex. Treatment of SKBR-3 cells (0, 0.001, 0.01, 0.1, 0.5, 1 and 10 μM) with celastrol, 
gedunin and H2-gamendazole decreased the cdc37 in co-immunoprecipitated with Hsp90 
with the increasing concentrations of the compounds, as shown by western blot analysis of 
the coimmunoprecipitate (Hsp90 IP).
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Regulation of client proteins involved in the proliferation of MCF-7 cell. MCF-7 cells were 
grown to confluence as described above, seeded in culture dishes (1×106/dish) for overnight 
to attach (37°C, 5% CO2). Compounds were added to the cell at varying concentrations and 
incubated for 48 h. Cells were harvested and analyzed for the Hsp90 client protein as 
described in experimental.
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Flow chart depicting systematic protocol for Hsp90 characterization. A lead compound is 
identified as an Hsp90 modulator and first evaluated for its effects on Hsp90 during trypsin 
proteolysis. Compounds will elicit proteolysis fingerprints similar to NB, wild type Hsp90, 
or neither (other). Next, several concentrations of the compound are used to elute Hsp90 off 
of GDA or NB bound sepharose beads during affinity chromatography. Again, compounds 
in each class should demonstrate behavior similar to NB, GDA, or neither (other). Finally, 
after evaluation in the β-galactosidase assay, compounds can be classified as C-terminal 
binders, N-terminal binders, or other, and further broken down into preventers, inducers, or 
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those exhibiting no effect on the heat shock response. After these three initial evaluations, 
compounds in the “other” class can be characterized more specifically via co-
immunoprecipitation, western blot analysis, NMR analysis, X-ray crystallographic 
techniques, etc… to determine the precise mode of action such, as allosteric modulator, co-
chaperone disruptor, client protein disruptor, or other.
Evaluation of the Heat Shock Response in Yeast PP30 Cells Due to Select Modulators with 
and without Heat Stress.
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Table 1
OPAL prediction.
Type of site Location P3-P2-P1-P1′*
Class 1 291 WNRD
Class 3 398 IAKL
Class 3 616 FIRR
Class 4 617 IRRM
Class 1–4: Fastest to slowest cleavage,
*
P1-P1′ is the cleavage site













Matts et al. Page 27
Table 2
The solvent accessible surface area of the cleavage site residues.
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